Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.

"Declarations Ethics approval and consent to participateThis study was approved by the institutional review board of Kaohsiung Medical University Hospital (KMU-HIRB-2013132) and conducted in accordance with the Good Clinical Practice guidelines. Written informed consent was obtained from all participants before recruitment. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no conflict of interest. Competing interests The authors declare that they have no conflict of interest."

"Funding This work was supported by the National Science and Technology Council of Taiwan (grant nos: 111-2320-B-039-021-MY3, 111-2218-E-037-001, 112-2311-B-039-001, and 112-2218-E-037-001), the Kaohsiung Medical University (grant no: NHRIKMU-111-I002 and KMUH112-2R59), and the China Medical University (grant nos: CMU111-MF-09, CMU111-TC-08, CMU112-MF-10, and CMU112-MF-108). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."